Dasselta

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Risalah maklumat Risalah maklumat (PIL)
09-06-2022
Ciri produk Ciri produk (SPC)
09-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam (PAR)
15-12-2011

Bahan aktif:

desloratadine

Boleh didapati daripada:

Krka, d.d., Novo mesto

Kod ATC:

R06AX27

INN (Nama Antarabangsa):

desloratadine

Kumpulan terapeutik:

Antihistamines for systemic use,

Kawasan terapeutik:

Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal; Urticaria

Tanda-tanda terapeutik:

Dasselta is indicated for the relief of symptoms associated with:allergic rhinitis;urticaria.

Ringkasan produk:

Revision: 13

Status kebenaran:

Authorised

Tarikh kebenaran:

2011-11-28

Risalah maklumat

                                19
B. PACKAGE LEAFLET
20
PACKAGE LEAFLET: INFORMATION FOR THE USER
DASSELTA 5 MG FILM-COATED TABLETS
desloratadine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Dasselta is and what it is used for
2.
What you need to know before you take Dasselta
3.
How to take Dasselta
4.
Possible side effects
5.
How to store Dasselta
6.
Contents of the pack and other information
1.
WHAT DASSELTA IS AND WHAT IT IS USED FOR
WHAT DASSELTA IS
Dasselta contains desloratadine which is an antihistamine.
HOW DASSELTA WORKS
Dasselta is an antiallergy medicine that does not make you drowsy. It
helps control your allergic
reaction and its symptoms.
WHEN DASSELTA SHOULD BE USED
Dasselta relieves symptoms associated with allergic rhinitis
(inflammation of the nasal passages
caused by an allergy, for example, hay fever or allergy to dust mites)
in adults and adolescents 12
years of age and older. These symptoms include sneezing, runny or
itchy nose, itchy palate, and itchy,
red or watery eyes.
Dasselta is also used to relieve the symptoms associated with
urticaria (a skin condition caused by an
allergy). These symptoms include itching and hives.
Relief of these symptoms lasts a full day and helps you to resume your
normal daily activities and
sleep.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE DASSELTA
DO NOT TAKE DASSELTA
-
if you are allergic to desloratadine, to any of the other ingredients
of this medicine (listed in
section 6) or to loratadine.
WARNINGS AND PRECAUTIONS
Talk to your doctor or pharmacist before taking Dass
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Dasselta 5 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 5 mg desloratadine.
Excipient with known effect:
Each film-coated tablet contains 16.15 mg lactose (as monohydrate).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Light blue, round, film-coated tablets with beveled edges (diameter:
6.5 mm, thickness: 2.3–3.5 mm).
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Dasselta is indicated in adults and adolescents aged 12 years and
older for the relief of symptoms
associated with:
-
allergic rhinitis (see section 5.1),
-
urticaria (see section 5.1).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Adults and adolescents (12 years of age and over)_
The recommended dose of Dasselta is one tablet once a day.
Intermittent allergic rhinitis (presence of symptoms for less than 4
days per week or for less than
4 weeks) should be managed in accordance with the evaluation of
patient’s disease history and the
treatment could be discontinued after symptoms are resolved and
reinitiated upon their reappearance.
In persistent allergic rhinitis (presence of symptoms for 4 days or
more per week and for more than
4 weeks), continued treatment may be proposed to the patients during
the allergen exposure periods.
_Paediatric population _
There is limited clinical trial efficacy experience with the use of
desloratadine in adolescents 12
through 17 years of age (see sections 4.8 and 5.1).
The safety and efficacy of Dasselta 5 mg film-coated tablets in
children below the age of 12 years
have not been established.
Method of administration
Oral use.
The tablet can be taken with or without food.
4.3
CONTRAINDICATIONS
Hypersensitivity to the active substance, to any of the excipients
listed in section 6.1 or to loratadine.
3
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
In the case of severe renal insufficiency, Dasselta should be used
with caution (se
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 09-06-2022
Ciri produk Ciri produk Bulgaria 09-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 15-12-2011
Risalah maklumat Risalah maklumat Sepanyol 09-06-2022
Ciri produk Ciri produk Sepanyol 09-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 15-12-2011
Risalah maklumat Risalah maklumat Czech 09-06-2022
Ciri produk Ciri produk Czech 09-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Czech 15-12-2011
Risalah maklumat Risalah maklumat Denmark 09-06-2022
Ciri produk Ciri produk Denmark 09-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 15-12-2011
Risalah maklumat Risalah maklumat Jerman 09-06-2022
Ciri produk Ciri produk Jerman 09-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 15-12-2011
Risalah maklumat Risalah maklumat Estonia 09-06-2022
Ciri produk Ciri produk Estonia 09-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 15-12-2011
Risalah maklumat Risalah maklumat Greek 09-06-2022
Ciri produk Ciri produk Greek 09-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Greek 15-12-2011
Risalah maklumat Risalah maklumat Perancis 09-06-2022
Ciri produk Ciri produk Perancis 09-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 15-12-2011
Risalah maklumat Risalah maklumat Itali 09-06-2022
Ciri produk Ciri produk Itali 09-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Itali 15-12-2011
Risalah maklumat Risalah maklumat Latvia 09-06-2022
Ciri produk Ciri produk Latvia 09-06-2022
Risalah maklumat Risalah maklumat Lithuania 09-06-2022
Ciri produk Ciri produk Lithuania 09-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 15-12-2011
Risalah maklumat Risalah maklumat Hungary 09-06-2022
Ciri produk Ciri produk Hungary 09-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 15-12-2011
Risalah maklumat Risalah maklumat Malta 09-06-2022
Ciri produk Ciri produk Malta 09-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Malta 15-12-2011
Risalah maklumat Risalah maklumat Belanda 09-06-2022
Ciri produk Ciri produk Belanda 09-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 15-12-2011
Risalah maklumat Risalah maklumat Poland 09-06-2022
Ciri produk Ciri produk Poland 09-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Poland 15-12-2011
Risalah maklumat Risalah maklumat Portugis 09-06-2022
Ciri produk Ciri produk Portugis 09-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 15-12-2011
Risalah maklumat Risalah maklumat Romania 09-06-2022
Ciri produk Ciri produk Romania 09-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Romania 15-12-2011
Risalah maklumat Risalah maklumat Slovak 09-06-2022
Ciri produk Ciri produk Slovak 09-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 15-12-2011
Risalah maklumat Risalah maklumat Slovenia 09-06-2022
Ciri produk Ciri produk Slovenia 09-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 15-12-2011
Risalah maklumat Risalah maklumat Finland 09-06-2022
Ciri produk Ciri produk Finland 09-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Finland 15-12-2011
Risalah maklumat Risalah maklumat Sweden 09-06-2022
Ciri produk Ciri produk Sweden 09-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 15-12-2011
Risalah maklumat Risalah maklumat Norway 09-06-2022
Ciri produk Ciri produk Norway 09-06-2022
Risalah maklumat Risalah maklumat Iceland 09-06-2022
Ciri produk Ciri produk Iceland 09-06-2022
Risalah maklumat Risalah maklumat Croat 09-06-2022
Ciri produk Ciri produk Croat 09-06-2022

Cari amaran yang berkaitan dengan produk ini

Lihat sejarah dokumen